The Capital Fund Management S.A. Acquires New Stake in Relypsa Inc. (RLYP)

The Capital Fund Management S.A. Acquires New Stake in Relypsa Inc. (RLYP)

Capital Fund Management S.A. purchased a new position in Relypsa Inc. (NASDAQ:RLYP) during the second quarter, Holdings Channel reports. The fund purchased 20,034 shares of the company’s stock, valued at approximately $371,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in RLYP. State Street Corp boosted its position in shares of Relypsa by 106.1% in the first quarter. State Street Corp now owns 2,216,498 shares of the company’s stock worth $30,037,000 after buying an additional 1,141,229 shares in the last quarter. Deerfield Management Co. boosted its position in shares of Relypsa by 108.1% in the first quarter. Deerfield Management Co. now owns 1,873,471 shares of the company’s stock worth $25,386,000 after buying an additional 973,190 shares in the last quarter. Scopia Capital Management LP acquired a new position in shares of Relypsa during the first quarter worth approximately $4,930,000. BlackRock Fund Advisors boosted its position in shares of Relypsa by 11.5% in the first quarter. BlackRock Fund Advisors now owns 1,773,301 shares of the company’s stock worth $24,028,000 after buying an additional 182,193 shares in the last quarter. Finally, UBS Asset Management Americas Inc. boosted its position in shares of Relypsa by 20.3% in the first quarter. UBS Asset Management Americas Inc. now owns 515,790 shares of the company’s stock worth $6,989,000 after buying an additional 86,890 shares in the last quarter.

Relypsa Inc. (NASDAQ:RLYP) remained flat at $31.99 during mid-day trading on Friday. The firm has a 50-day moving average of $30.31 and a 200-day moving average of $20.28. Relypsa Inc. has a 1-year low of $10.26 and a 1-year high of $32.12.

Relypsa (NASDAQ:RLYP) last released its quarterly earnings data on Thursday, August 4th. The company reported ($1.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by $0.31. The business had revenue of $5.22 million for the quarter, compared to analysts’ expectations of $5.45 million. On average, equities research analysts forecast that Relypsa Inc. will post ($6.33) earnings per share for the current fiscal year.

A number of research analysts have commented on RLYP shares. Vetr upgraded shares of Relypsa from a “strong sell” rating to a “strong-buy” rating and set a $22.45 price target for the company in a research note on Wednesday, June 22nd. Stifel Nicolaus reaffirmed a “buy” rating and set a $36.00 price objective on shares of Relypsa in a report on Friday, July 15th. BTIG Research reaffirmed a “buy” rating and set a $35.00 price objective on shares of Relypsa in a report on Wednesday, June 29th. Wedbush reaffirmed an “outperform” rating and set a $51.00 price objective on shares of Relypsa in a report on Thursday, July 21st. Finally, Cantor Fitzgerald set a $41.00 price objective on shares of Relypsa and gave the stock a “buy” rating in a report on Thursday, July 21st. Twelve equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $35.87.

In other Relypsa news, major shareholder Orbimed Advisors Llc sold 4,043,600 shares of the firm’s stock in a transaction on Monday, July 25th. The shares were sold at an average price of $32.00, for a total value of $129,395,200.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder James D. Dondero sold 37,000 shares of the firm’s stock in a transaction on Thursday, August 11th. The shares were sold at an average price of $31.96, for a total transaction of $1,182,520.00. The disclosure for this sale can be found here.

Relypsa Company Profile

Relypsa, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients’ lives and even be life-threatening. The Company’s first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia.

Related posts

Leave a Comment